Table 3

Reduction in diarrhoea duration among Guatemalan children treated with PTM202 versus placebo, according to the presence of pathogens targeted directly or indirectly by the nutritional intervention.

Pathogen	Intervention	n	Median hours	HR	95% CI	P value
All Sites
All pathogens	PTM202	154	26.7	1.10	0.88 to 1.39	0.40
All pathogens	Placebo	147	28.2	1.10	0.88 to 1.39	0.40
Directly targeted*	PTM202	78	25.5	1.46	1.07 to 2.00	0.02
Directly targeted*	Placebo	85	28.7	1.46	1.07 to 2.00	0.02
Directly and indirectly targeted†	PTM202	120	25.9	1.30	1.01 to 1.69	0.04
Directly and indirectly targeted†	Placebo	119	28.7	1.30	1.01 to 1.69	0.04
Urban
All pathogens	PTM202	71	26.4	1.30	0.93 to 1.83	0.13
All pathogens	Placebo	64	33.5	1.30	0.93 to 1.83	0.13
Directly targeted*	PTM202	25	21.5	2.20	1.24 to 3.90	0.007
Directly targeted*	Placebo	28	33.4	2.20	1.24 to 3.90	0.007
Directly and Indirectly targeted†	PTM202	48	25.2	1.96	1.28 to 3.01	0.002
Directly and Indirectly targeted†	Placebo	47	33.8	1.96	1.28 to 3.01	0.002
Rural
All pathogens	PTM202	83	28.2	0.95	0.70 to 1.29	0.75
All pathogens	Placebo	83	26.6	0.95	0.70 to 1.29	0.75
Directly targeted*	PTM202	53	26.3	1.26	0.86 to 1.85	0.23
Directly targeted*	Placebo	57	27.3	1.26	0.86 to 1.85	0.23
Directly and indirectly targeted†	PTM202	72	28.7	1.05	0.76 to 1.47	0.75
Directly and indirectly targeted†	Placebo	72	27.2	1.05	0.76 to 1.47	0.75

*Directly targeted pathogens (enterotoxigenic Escherichia coli, Shiga toxin-positive E. coli, E. coli 0157, Salmonella or Rotavirus) present at baseline.
†Directly or indirectly targeted pathogens (enterotoxigenic Escherichia coli, Shiga toxin-positive E. coli, E. coli 0157, Salmonella, Rotavirus, norovirus or Shigella (enteroinvasive E. coli)) present at baseline.